Last reviewed · How we verify

Part 2: Nonaerosol Spray

Food and Drug Administration (FDA) · Phase 1 active Small molecule

Part 2: Nonaerosol Spray is a Small molecule drug developed by Food and Drug Administration (FDA). It is currently in Phase 1 development. Also known as: Avobenzone, Octocrylene, Homosalate, Octisalate.

At a glance

Generic namePart 2: Nonaerosol Spray
Also known asAvobenzone, Octocrylene, Homosalate, Octisalate, Octinoxate
SponsorFood and Drug Administration (FDA)
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Part 2: Nonaerosol Spray

What is Part 2: Nonaerosol Spray?

Part 2: Nonaerosol Spray is a Small molecule drug developed by Food and Drug Administration (FDA).

Who makes Part 2: Nonaerosol Spray?

Part 2: Nonaerosol Spray is developed by Food and Drug Administration (FDA) (see full Food and Drug Administration (FDA) pipeline at /company/food-and-drug-administration-fda).

Is Part 2: Nonaerosol Spray also known as anything else?

Part 2: Nonaerosol Spray is also known as Avobenzone, Octocrylene, Homosalate, Octisalate, Octinoxate.

What development phase is Part 2: Nonaerosol Spray in?

Part 2: Nonaerosol Spray is in Phase 1.

Related